PETV · XBRL financial data

PetVivo Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PETV's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue from contracts with customers	13	116	917	969	1,133	1,142
Cost of goods and services sold	11	201	527	229	138	387
Gross profit	2	(86)	390	740	995	755
Research and development	98	475	691	1,268	1,583	1,415
General and administrative	1,768	3,148	5,023	6,693	4,823	4,334
Total operating expenses	1,961	4,971	9,124	11,361	9,051	9,818
Operating income (loss)	(1,959)	(5,057)	(8,733)	(10,621)	(8,056)	(9,063)
Interest income	—	—	—	—	—	13
Interest expense	229	—	—	—	6	13
Net income (loss)	(3,523)	(5,015)	(8,718)	(10,955)	(8,399)	(10,474)
Earnings per share, basic USD per share	(0.57)	(0.57)	(0.85)	(0.78)	(0.41)	(0.38)
Earnings per share, diluted USD per share	—	—	(0.85)	(0.78)	(0.41)	(0.38)
Weighted average shares, basic thousands of shares	6,199	8,761	10,223	13,970	20,491	30,155
Weighted average shares, diluted thousands of shares	—	—	10,223	13,970	20,491	30,155

Fiscal years (PETV's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	24	6,107	475	87	228	201
Short-term investments	—	—	—	—	150	150
Accounts receivable	—	3	87	19	61	101
Inventory	—	98	370	390	324	538
Prepaid and other current assets	124	548	492	546	448	270
Total current assets	147	6,755	1,424	1,042	5,610	1,860
Property and equipment, net	214	312	631	822	767	449
Right-of-use asset	158	299	318	1,194	962	55
Total assets	835	7,427	2,439	3,115	9,339	3,577
Accounts payable	741	323	589	821	821	547
Accrued liabilities	554	784	780	243	949	454
Total current liabilities	1,405	1,173	1,454	1,412	4,317	1,377
Lease liability, non-current	131	240	240	1,004	798	—
Total liabilities	1,732	1,441	1,714	2,429	5,120	1,377
Accumulated deficit	(58,111)	(63,126)	(71,844)	(82,799)	(91,198)	(102,076)
Total stockholders' equity	(897)	5,987	725	686	4,219	2,199
Total liabilities and equity	835	7,427	2,439	3,115	9,339	3,577
Common shares outstanding (cover page) thousands of shares	7,050	9,988	11,824	19,905	24,389	37,594

Fiscal years (PETV's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	(3,523)	(5,015)	(8,718)	(10,955)	(8,399)	(10,474)
Stock-based compensation	453	703	1,463	2,110	1,108	1,880
Depreciation and amortization	87	65	114	127	175	511
Net cash from operating activities	(1,047)	(4,175)	(6,794)	(7,420)	(5,322)	(6,107)
Purchases of property and equipment	141	154	424	309	63	8
Net cash from investing activities	(160)	(183)	(424)	(309)	(563)	12
Proceeds from issuing common stock	317	—	138	6,527	2,050	675
Proceeds from issuing equity	317	10,201	—	—	—	—
Net cash from financing activities	1,220	10,441	1,587	7,341	6,026	6,069
Net change in cash	13	6,083	(5,632)	(388)	140	(27)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
Guided Therapeutics	12	0	(319)*	96.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.